In a business update, Carmat announces that it expects to reach a production capacity of 500 prostheses in 2024 and 1,000 prostheses by 2027, as well as its break-even point within five years, in 2027.

After resuming its commercial operations, the Aeson artificial heart designer is continuing to set up new hospitals, with a target of 30 operational centers in Europe, mainly in Germany and Italy, by the end of 2023.

The ramp-up in production will be gradual, and should enable the production of over 100 artificial hearts by 2023. On this basis, Carmat anticipates sales of 10 to 13 million euros this year.

Copyright (c) 2023 CercleFinance.com. All rights reserved.